Newronika, a leader in advanced deep brain stimulation, announced the closing of its €13.6 million Series B funding round. This funding was led by new investor Fondazione ENEA Tech e Biomedical, with additional participation from existing investors Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F.
This significant funding will enable Newronika to expand the clinical validation and commercialization of its proprietary adaptive DBS system, an innovative platform designed to deliver precision therapy aimed at improving symptom relief and reducing side effects for Parkinson’s disease patients. The funding will also facilitate the advancement of product pipelines, recruiting top-tier talent, and establishing strategic collaborations that further strengthen the company’s position at the intersection of medical device engineering and neuroscience.
Newronika’s continued momentum as evidenced by recent The Michael J. Fox Foundation grant and IDE approval, and now a substantial funding round validates the company’s central mission: to champion a paradigm shift in neuromodulation. Adaptive DBS represents the future of personalized brain stimulation, and Newronika remains dedicated to leading that evolution.
KEY QUOTES:
“We are thrilled with the strong support from both new and existing investors. This Series B round validates our commitment to transform the way deep brain stimulation is delivered. We aim to seamlessly integrate real-time neural data and machine learning into our DBS systems to create truly personalized therapies that surpass the capabilities of existing devices on the market.”
- Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika
“With Newronika and its adaptive DBS platform, we see extraordinary potential to revolutionize the treatment of movement disorders on a global scale. Their innovative approach, capable of real-time, personalized neuromodulation, perfectly aligns with our vision of supporting disruptive medical technologies. We are excited to partner with Newronika to deliver next-generation DBS solutions to patients in need. Investing in technologies like this means caring for people’s health while creating value and driving innovation within our Country’s ecosystem.”
- Maria Cristina Porta, ENEA Tech e Biomedical General Manager
“Indaco is proud to continue supporting Newronika, also through its Indaco Venture I – Lombardia Parallel Fund, in the upcoming clinical and commercial phases. We strongly believe that Newronika’s adaptive DBS system will improve the quality of life for many Parkinson’s patients.”
- Davide Turco, CEO of Indaco
“This successful Series B financing round further solidifies Newronika’s strategic vision and commitment to pushing the boundaries of DBS technology to benefit patients.”
• ⁃ Claudio Giuliano, Chairman of Newronika
